The aim of the present work was to investigate and assess the merit of PEGylated recombinant human tumor necrosis factor-a a (rHuTNF-a a) following our previous work. The rHuTNF-a a was modified using activated polyethylene glycol (PEG), N-succinimidyl succinnate monomethoxy polyethylene glycol (SS-PEG). The pharmacokinetics and anti-tumor effect were investigated. The experimental results showed that PEGylated rHuTNF-a a could obviously alter in vivo behavioral characteristics of rHuTNF-a a. Among the synthesized PEG-rHuTNF-a as with different PEG molecules, PEG 20000 -rHuTNF-a a demonstrated the longest circulating half-life (24.8 h) which was about 50 times longer than that of rHuTNF-a a (28.8 min). In addition, there was much more PEG 20000 -rHuTNF-a a distributed into tumor tissues than other PEG-rHuTNF-a as or rHuTNF-a a with time, and PEG 20000 -rHuTNF-a a also showed the highest anti-tumor potency. These results indicated that PEG 20000 -rHuTNF-a a was a useful long circulating molecule with selective localization in tumor tissues and enhanced anti-tumor activity of rHuTNF-a a.
Tumor necrosis factor alpha (TNF-a) has attracted attention as a novel anti-tumor agent due to its striking biological effects, such as direct cytotoxicity against various tumor cells, activation of immune anti-tumor response and inducement of hemorrhaged necrosis of certain transplanted solid tumors. [1] [2] [3] However, TNF-a can rapidly be cleared from the blood with very short plasma half-life, and high doses are required to obtain significant anti-tumor effects because of its very low in vivo stability. In addition, it was found to have severe toxic side effects in phase I-II studies, for example, tissue inflammation and injury, decrease in blood pressure, inhibition of gastric emptying, even a lethal endotoxic shocklike syndrome at very high doses. 4, 5) Therefore, when TNF-a was clinically used as a systemic anti-tumor agent, its dose was limited to 1/5-1/25 of the dose required for the development of anti-tumor effects.
In order to overcome these problems, it is a considerable strategy to utilize polyethylene glycol-conjugated pharmaceutical proteins which can improve their physicochemical, pharmacokinetic and biological properties to attain maximum clinical potency. 6) In recent years, some of the PEGylated proteins or peptides, such as PEGylated interferon (PEG-IFN), PEGylated interleukin-2 (PEG-IL-2) and PEGylated adenosine deaminase (PEG-ADA), have been used in clinical practice or studies and obtained good effects. [7] [8] [9] [10] [11] PEGylation of natural human TNF-a demonstrated that PEGylated natural human TNF-a had longer plasma half-life and better anti-tumor potency than free natural human TNFa; in particular, PEGylated natural human TNF-a showed much lower side effects. [12] [13] [14] [15] [16] [17] [18] Unfortunately, natural human TNF-a is very expensive and limited in source. On the contrary, recombinant human tumor necrosis factor-a (rHuTNFa) is very rich in resources with the development of gene-engineering technology. However, there are some differences between natural human TNF-a and rHuTNF-a, such as molecular size and number of amino acids, etc. These differences can cause different properties between PEGylated natural human TNF-a and PEGylated rHuTNF-a. Thus, it is very essential to study PEGylated rHuTNF-a.
The purpose of the present work was to further investigate and assess the merits of PEGylated rHuTNF-a following our previous work.
19 ) The pharmacokinetics and anti-tumor effects of PEGylated rHuTNF-a were investigated. The results of this study will provide fundamental information enabling us to design useful PEGylated rHuTNF-a with long circulation half-life and selective localization in tumor tissues.
MATERIALS AND METHODS

Materials
Recombinant human tumor necrosis factor-a (rHuTNF-a, MWϭ17000) was obtained from Shanghai Research Center of Biotechnology, Chinese Academy of Sciences (Shanghai, China). N-succinimidyl succinnate monomethoxy polyethylene glycol (SS-PEG, MWϭ5000, 12000 and 20000) was purchased from Nippon Oil and Fats (Tokyo, Japan). e-Amino-caproic acid and carrier-free Na 125 I were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Other reagents and solvents were of analytical grade.
Animals and Cells Female Kunming strain mice (20Ϯ2 g) were supplied by Shanghai Experimental Animal Center, Chinese Academy of Sciences (Shanghai, China ). The animals were acclimatized at a temperature of 25Ϯ2°C and a relative humidity of 70Ϯ5% under natural light/dark conditions for one week before dosing. L929 cells were kindly supplied by Shanghai Research Center of Biotechnology, Chinese Academy of Sciences (Shanghai, China), and serially subcultured in a RPMI-1640 medium with 10% (v/v) fetal calf serum. Sarcoma-180 cells were maintained intraperitoneally in Kunming mice.
Conjugation of PEG to rHuTNF-a a PEGylated rHuTNF-a (PEG-rHuTNF-a) was prepared using the procedure as described elsewhere. 19 Xiu-Jian GAO, a and Jian-Hua ZHU min. Then, the reaction was stopped by adding 5-fold molar excess of e-amino-caproic acid over SS-PEG. The resulting PEG-rHuTNF-a was separated into fractions of various molecular weights by gel filtration chromatography. The molecular weight of separated PEG-rHuTNF-a was estimated by GFC analysis with protein standard and the numbers of PEG conjugated to rHuTNF-a were calculated from the molecular weight of PEG-rHuTNF-a. In vitro activities of rHuTNF-a and PEG-rHuTNF-a were determined with L929 cells.
2) The protein concentration of rHuTNF-a and PEG-rHuTNF-a was determined by the method of Bradford.
20) Different concentrations of bovine serum albumin (BSA) were used for the standard curve. The main fractions of PEG-rHuTNF-a with different PEG molecules were used for investigating pharmacokinetics and anti-tumor activity described as follows.
Radioiodination of rHuTNF-a a and PEG-rHuTNF-a a The rHuTNF-a was labeled with 125 I using the IODO-GEN procedure. Briefly, 60 mg of protein in 50 ml 0.1 M potassium phosphate buffer (pH 7.2) was layered over a freshly prepared film of IODO-GEN (100 mg) and incubated for 10 min at 4°C in the presence of 1 mCi of carrier-free Na 125 I. The reaction mixture was brought up to 0.5 ml volume with PBS, and the unreacted iodine was removed by gel filtration chromatography on a Sephadex G-25 PD10 column equilibrated with PBS. The specific radioactivity of the product was assessed in an autogamma (Packard Instruments, CT, U.S.A.). The 125 I-iodinated rHuTNF-a and PEG-rHuTNF-a were used for the study of pharmacokinetics described as follows.
Pharmacokinetics of PEG-rHuTNF-a a Four groups of female Kunming strain mice were used in this experiment, group 1 being treated with 125 I-rHuTNF-a and groups 2-4 with the main fractions of 125 I-PEG 5000 -rHuTNF-a, 125 I-PEG 12000 -rHuTNF-a, and 125 I-PEG 20000 -rHuTNF-a, respectively. For administration, 125 I-rHuTNF-a and 125 I-PEGrHuTNF-a were prepared into the same concentration of protein, and each animal was given intravenously at the dose of 0.5 mg protein with a trace of 125 I (1 mCi). After intravenous administration, blood was collected at 0.25, 0.5, 1, 2, 3, 6, 12 and 24 h from the tail vein and the radioactivity levels were measured. The pharmacokinetic parameters of rHuTNF-a and PEG-rHuTNF-a were calculated using the Practical Pharmacokinetic Program-Version 87.
In order to study the tissue distribution, eight groups of female Kunming strain mice with S-180 tumor nodules of 9-10 mm in diameter were used. The groups 1-2 were treated with 125 I-rHuTNF-a and groups 3-8 with the main fractions of 125 I-PEG 5000 -rHuTNF-a, 125 I-PEG 12000 -rHuTNF-a and 125 I-PEG 20000 -rHuTNF-a, respectively. Each animal was given intravenously at the dose of 0.5 mg protein with a trace of 125 I (1 mCi). The mice were dehematized of the abdominal aorta at 1 h and 6h after intravenous injection. Tissues were collected and weighted and the radioactivities were measured.
Anti-tumor Activity of PEG-rHuTNF-a a Eight groups of female Kunming strain mice (nϭ10) were used, and sarcoma-180 (S-180) cells were implanted intradermally into the armpit of the mice. After 7 d, when the tumor nodules had grown to 9-10 mm in diameter, rHuTNF-a and PEGrHuTNF-a were given by intravenous injection once every 2 days for 8 d. The group 1 was treated with saline, groups 2-5 with rHuTNF-a at the doses of 0.1, 0.5, 1 and 2 mg per mouse, respectively, and the groups 6-8 with the main fractions of PEG 5000 -rHuTNF-a, PEG 12000 -rHuTNF-a and PEG 20000 -rHuTNF-a at the dose of 0.5 mg protein per mouse, respectively. Anti-tumor effects against S-180 solid tumor were expressed according to mean relative tumor volume and survival days. Tumor volume was calculated by the formula as previously described.
21)
Statistical analysis Statistical evaluations of tumor volume and survival days were analyzed by using Student's t test.
RESULTS
The main fractions of PEG-rHuTNF-a with different PEG molecules were obtained by gel filtration chromatography in this paper through our previous work.
19 ) The main fraction of PEG 5000 -rHuTNF-a contained four PEG molecules with molecular weight 37000 and 49.3% remaining activity. The main fractions of PEG 12000 -rHuTNF-a and PEG 20000 -rHuTNF-a contained two PEG molecules with MW 41000 (58.7% remaining activity) and 57000 (37.8% remaining activity), respectively.
The plasma curves of rHuTNF-a and PEG-rHuTNF-a after intravenous injection were shown in Fig. 1 . The radioactivities in plasma at 2 h after intravenous administration of PEG 5000 -rHuTNF-a, PEG 12000 -rHuTNF-a and PEG 20000 -rHuTNF-a were about 3.5, 6.3 and 8.4 folds of that observed for free rHuTNF-a, respectively. All of PEG-rHuTNF-as exhibited delayed blood clearance. The much higher blood-associated radioactivity (99.5 cpm/ml) of PEG 20000 -rHuTNF-a could be seen at 24 h compared to that of PEG 5000 -rHuTNF-a (3.9 cpm/ml) or PEG 12000 -rHuTNF-a (15.9 cpm/ml), but rHuTNF-a was quickly removed from the circulation system. The radioactivity-time curves for all of PEG-rHuTNFas in mice were fitted with a two-compartment model and their pharmacokinetic parameters were shown in Table 1 . The plasma half-lives of PEG 5000 -rHuTNF-a, PEG 12000 -rHuTNF-a and PEG 20000 -rHuTNF-a were 6.3 h, 9.3 h and 24.8 h, respectively. The radioactivity-time curve of rHuTNF-a after intravenous injection in mice was fitted with a one-compartment model and its pharmacokinetic parameters were shown in Table 2 . Its half-life was only 28.8 min.
The distribution profiles of 125 I-labeled rHuTNF-a and 125 I-labeled PEG-rHuTNF-a in S-180 solid tumor-bearing mice after intravenous administration were shown in Fig. 2 . At 1 h after intravenous administration, rHuTNF-a was distributed to normal tissues, successively, liverϾspleenϾlungϾ kidney. The tumor accumulation of rHuTNF-a was very low. At 6 h after intravenous injection, rHuTNF-a was markedly eliminated from all tissues. There were no large differences in distribution of PEG-rHuTNF-as compared with rHuTNFa in normal tissues, but plasma levels of PEG-rHuTNF-as were markedly higher than that of rHuTNF-a at the same time point. Their tumor accumulations were time-dependently increased. At 1 h after intravenous injection, tumor accumulation of PEG-rHuTNF-a was not obviously different from rHuTNF-a, but tumor accumulation of PEG-rHuTNFa dramatically increased at 6h, which was higher than that of rHuTNF-a and increased with the attached PEG molecular weight. The inhibitory action of PEG-rHuTNF-a against S-180 solid tumors in mice was shown in Fig. 3 . The rHuTNF-a at doses of 1.0 and 2.0 mg per mouse induced the obvious antitumor response, but did not extend survival days and complete regression was at a dose of 2.0 mg per mouse (Table 3 ). In addition, 1 mouse and 3 mice died at the tenth day for rHuTNF-a at doses of 1.0 and 2.0 mg per mouse, respectively. The other surviving mice developed piloerection and a transient decrease in body weight (data not shown). PEG 5000 -rHuTNF-a had a similar tumor growth inhibitory action compared with rHuTNF-a (2.0 mg per mouse) (pϾ0.05), but could extend survival days (Table 3) . PEG 12000 -rHuTNF-a had more obvious inhibitory action to S-180 solid tumor growth compared with rHuTNF-a (2.0 mg per mouse) (pϽ 0.05) and obviously extended survival days (Table 3) . PEG 20000 -rHuTNF-a had the highest anti-tumor potency with the tumor growth in most of the mice inhibited completely, and the survival days of mice were also the longest (36.6 days) (Table 3) . For all PEG-rHuTNF-as, the relative tumor volume in mice treated with PEG-rHuTNF-a was decreased gradually with the molecular size of PEG-rHuTNF-a increased. During the experimental period, all PEG-rHuTNFas were tolerated well, and body weight reduction and other rHuTNF-a mediated side-effects were not observed (data not shown). Saline and rHuTNF-a (0.1 mg per mouse) did not inhibit tumor growth (Fig. 3) .
DISCUSSION
In general, PEGylated protein or peptide differs from the parent molecule in physicochemical, pharmacokinetic and biological properties. In this paper, it was found that in vivo behavior of rHuTNF-a was altered after being combined with PEG molecules. The radioactivity-time curves of PEGrHuTNF-as were fitted with a two-compartment model, but that of rHuTNF-a was fitted with a one-compartment model. The plasma half-lives of PEG-rHuTNF-as were longer than that of rHuTNF-a and extended with molecular size of PEGrHuTNF-a: the bigger molecular size, the longer half-life. 668 Vol. 24, No. 6 Table 2 . Pharmacokinetic Parameters of rHuTNF-a in Mice The same phenomenon was also observed with natural tumor necrosis factor-a. 14, 15) The accumulated amount of PEGrHuTNF-a in tumors time-dependently increased, whereas the distribution of PEG-rHuTNF-a to normal tissues decreased over time. At 6 h after intravenous injection, the order of the amount distributed in the tumor was PEG 20000 -rHuTNF-aϾPEG 12000 -rHuTNF-aϾPEG 5000 -rHuTNF-a. It showed an obvious relationship between the amount of PEGrHuTNF-a distributed to tumor tissues and the molecular size of PEG-rHuTNF-a.
PEG 20000 -rHuTNF-a (molecular size, 57000) showed the highest anti-tumor potency among the synthesized PEGrHuTNF-as. This result might result from its highest accumulation in tumor tissues and longest plasma circulating time. It is well known that TNF-a can induce the hemorrhagic necrosis of tumors via specific interactions with tumor-vascular endothelial cells, and it also has direct cytotoxicity against various tumor cells and stimulates the host immune anti-tumor response. Thus, an increase in tumor accumulation and prolongation of the plasma half-life must produce higher anti-tumor potency. It was reported that the permeability of tumor vascularization was enhanced compared with that of normal tissues, so macromolecules such as albumin (molecular size, 69000) was prone to accumulate in the tumor, 22) but excessively large molecules such as IgG (molecular size, 150000) accumulated in poor tumors. 23) On the other hand, TNF-a selectively enhanced tumor-vascular permeability, whereas the normal vascularization was not affected by TNF-a . 24) Additionally, it was found in our previous work that higher activity remained if PEG-rHuTNF-a contained fewer PEG molecules with the same molecular weight.
19) It also was reported that PEGylated natural TNFa, which was drastically transported and accumulated in the tumor, augmented its antitumor potency with a molecular size from 84000 to 122000. 17) Thus, an even higher antitumor effect of PEG-rHuTNF-a could be obtained by further increasing molecular size of PEG-rHuTNF-a containing fewer PEG molecules with the same molecular weight, which is being investigated in our laboratory.
In conclusion, PEG-modified rHuTNF-a could obviously alter in vivo behavioral characteristics of rHuTNF-a. Among all of the PEG-rHuTNF-as, PEG 20000 -rHuTNF-a exhibited the longest plasma half-life, which was about 50 fold that of rHuTNF-a. This difference could be caused by the steric hindrance of PEG chain. In addition, there was much more PEG 20000 -rHuTNF-a distributed to tumor tissues than other PEG-rHuTNF-a or rHuTNF-a with time, and PEG 20000 -rHuTNF-a also showed the highest anti-tumor potency. These results demonstrated that PEG 20000 -rHuTNF-a was a useful long circulating PEGylated rHuTNF-a molecule with selective localization in tumor tissue and helpful in enhancing antitumor activity of rHuTNF-a. 
